- Trial Phase
- Commercially launched (RUO) - not subject to clinical trial phases
- Time to Market
- Already commercially available as a research-use-only (RUO) product since April 2024
- Why 4/10
- ImmuneSelect is already a commercially-launched RUO product with no pending PDUFA or pivotal readout. The next catalyst is commercial execution under the new Fosun Diagnostics supply deal signed July 9, 2026, plus a potential ViraxImmune FDA pre-submission outcome (though that's a separate platform). Without a hard dated binary, ImpactScore defaults to 4.
ImmuneSelect is a very early-stage commercial product ($12K revenue FY2026) whose latest Fosun deal drove a 100%+ single-day stock surge. The stock is a high-risk microcap with a 1-for-25 reverse split just completed, negative retained earnings, and extremely high short-borrow fees (~107%). Watch for any disclosed purchase-order revenue from the Fosun deal in upcoming filings — that's the key tangible milestone to validate the commercial thesis.
Price Chart
Executive Summary
ImmuneSelect is Virax Biolabs' commercially available research-use-only (RUO) T-cell immune profiling product line — not a drug. Launched in April 2024, it includes ELISpot assay plates, peptide pools, and antibodies sold to academic and pharma researchers for immune monitoring. On July 9, 2026, Virax signed an exclusive multi-country supply agreement with Fosun Diagnostics covering six Southeast Asian markets, driving the stock up 100%+ in a single session. However, Virax remains a development-stage company with only $12K in FY2026 revenue, a $5M annual net loss, an accumulated deficit exceeding $24M, and a recent 1-for-25 reverse stock split to maintain Nasdaq listing. The product faces entrenched competition from established ELISpot/FluoroSpot suppliers, and the Fosun deal's financial terms (volume-based tiers with performance-linked exclusivity) have no disclosed minimums, making near-term revenue impact uncertain.
How It Works
ImmuneSelect is not a drug — it's a laboratory test kit (research-use-only) that helps scientists measure T-cell activity. It uses techniques like ELISpot (a method to count immune cells that react to a specific threat) to study how the immune system responds to viruses, vaccines, or other triggers. Researchers buy these kits to run experiments; they are not yet FDA-approved for diagnosing patients in a clinical setting.
Trial Status
ImmuneSelect is not a drug in clinical trials. It is a commercially available research-use-only (RUO) immune profiling product line launched in April 2024 at the ESCMID Global Congress. The product includes ELISpot assay plates, peptide pools, and antibodies for measuring T-cell immune responses. It is distinct from ViraxImmune, the company's separate in-development clinical diagnostic platform, which held an FDA pre-submission meeting in September 2025 for post-acute infection syndromes (PASC/Long COVID).
The Two-Sided Case
Upcoming Catalysts
- First purchase-order revenue disclosures under the Fosun Diagnostics deal (future SEC filings) — will validate whether the deal translates to material revenue.
- Potential expansion of the Fosun relationship into OEM manufacturing of ImmuneSelect products.
- ViraxImmune clinical diagnostic platform updates (separate from ImmuneSelect) — any FDA regulatory progress for the broader ViraxImmune platform could lift the entire stock.
- Future partnership announcements for additional geographic regions outside Southeast Asia.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Virax Biolabs Group Ltd 6-K VRAX ·Originating report